Log in

NASDAQ:OSMTOsmotica Pharmaceuticals Stock Price, Forecast & News

$2.94
-0.04 (-1.34 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.92
Now: $2.94
$3.16
50-Day Range
$2.83
MA: $4.78
$6.08
52-Week Range
$2.20
Now: $2.94
$7.97
Volume181,888 shs
Average Volume178,456 shs
Market Capitalization$151.47 million
P/E RatioN/A
Dividend YieldN/A
Beta4.18
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
CUSIPN/A
CIKN/A
Phone908-809-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240.03 million
Cash Flow$6.84 per share
Book Value$2.23 per share

Profitability

Net Income$-270,900,000.00
Net Margins-112.57%

Miscellaneous

Employees466
Market Cap$151.47 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.


Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

How has Osmotica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OSMT stock has decreased by 41.9% and is now trading at $2.94. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Osmotica Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Osmotica Pharmaceuticals.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Osmotica Pharmaceuticals.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) posted its quarterly earnings results on Wednesday, March, 18th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.52. The company had revenue of $59.91 million for the quarter, compared to analysts' expectations of $53.88 million. Osmotica Pharmaceuticals had a negative net margin of 112.57% and a negative return on equity of 5.97%. View Osmotica Pharmaceuticals' earnings history.

What price target have analysts set for OSMT?

6 brokerages have issued 1 year price targets for Osmotica Pharmaceuticals' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Osmotica Pharmaceuticals' stock price to reach $8.83 in the next year. This suggests a possible upside of 200.5% from the stock's current price. View analysts' price targets for Osmotica Pharmaceuticals.

Has Osmotica Pharmaceuticals been receiving favorable news coverage?

News stories about OSMT stock have trended very negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Osmotica Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutOsmotica Pharmaceuticals.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,300,000 shares, an increase of 18.2% from the February 13th total of 1,100,000 shares. Based on an average daily trading volume, of 386,600 shares, the days-to-cover ratio is currently 3.4 days. Approximately 11.7% of the shares of the stock are sold short. View Osmotica Pharmaceuticals' Current Options Chain.

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include SCYNEXIS (SCYX), Viking Therapeutics (VKTX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), Chiasma (CHMA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Primo Water (PRMW) and AT&T (T).

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
  • Mr. James D. Schaub, Exec. VP & COO (Age 37)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $2.94.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $151.47 million and generates $240.03 million in revenue each year. The company earns $-270,900,000.00 in net income (profit) each year or $0.25 on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe. View additional information about Osmotica Pharmaceuticals.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is http://www.osmotica.com/.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel